专利检索 ap:("BAYER PHARMA AKTIENGESELLSCHAFT") AND inv:"Peter ELLINGHAUS" 第 1 页

1.

发明申请
USE OF PAN FGFR INHIBITORS AND METHOD OF IDENTIFYING PATIENTS WITH CANCER ELIGIBLE FOR TREATMENT WITH A PAN FGFR INHIBITOR 审中-公开

公开(公告)号：US20180333418A1

公开(公告)日：2018-11-22

申请号：US15534033

申请日：2015-12-08

申请人： BAYER PHARMA AKTIENGESELLSCHAFT

发明人： Peter ELLINGHAUS , Melanie HEROULT

IPC分类号： A61K31/53 , C12Q1/6886 , A61K31/506 , A61K31/496 , A61K31/498 , A61K31/4184 , A61P35/00

CPC分类号： A61K31/53 , A61K31/4184 , A61K31/496 , A61K31/4965 , A61K31/498 , A61K31/506 , A61P35/00 , C12Q1/6886 , C12Q2600/106

摘要： The current invention is based on a pan FGFR inhibitor for use in the treatment of cancer in a subject, wherein the subject is one for whom the sum of FGFR1, FGFR2 and/or FGFR3 mRNA in a tumor tissue sample from the subject has been found to be overexpressed.